
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
EDITORIAL article
Front. Cell Dev. Biol. , 24 January 2025
Sec. Molecular and Cellular Pathology
Volume 13 - 2025 | https://doi.org/10.3389/fcell.2025.1556129
This article is part of the Research Topic Advancements in Proteomics and PTMomics: Unveiling Mechanistic Insights and Targeted Therapies for Metabolic Diseases View all 5 articles
Editorial on the Research Topic
Advancements in Proteomics and PTMomics: unveiling mechanistic insights and targeted therapies for metabolic diseases
The growing prevalence of metabolic diseases (including type 2 diabetes, hypertension, hyperlipidemia, obesity, and non-alcoholic fatty liver disease) poses a significant economic burden to our society (Chew et al., 2023). The pathogenesis of metabolic diseases is a multifactorial pathophysiological process arising from various systematic metabolic defects; therefore, a comprehensive, holistic approach is needed to deeply investigate the mechanisms associated with the development of metabolic diseases.
In the last 2 decades, proteomics, the large-scale study of proteins, has emerged as a powerful and useful tool to investigate the roles of proteins in biological systems. The rapid development of MS technologies has enabled a system-wide, qualitative, and quantitative analysis of the proteome at the cell, tissue, or organism level (Martinez-Val et al., 2022).
Proteomic studies can be classified in three main categories, i.e., expression, functional and structural proteomics. Expression proteomics involves the qualitative and quantitative comparison of protein expression in the entire proteome of samples from different states. Different MS-based quantitative proteomic techniques, such as SILAC, dimethyl labeling, iTRAQ, TMT, label-free, and DIA, have been applied to highlight differentially expressed proteins in different states, such as health and disease states. However, these MS-based quantitation methods are characterized by different features, advantages, and shortcomings (Chen et al., 2021). The choice of suitable quantitative methods is necessary for accurate and reliable results.
Post-translational modifications (PTMs) of proteins, the covalent modifications involving the addition or removal of chemical/protein groups on proteins, are highly important for the regulation of protein function, localization, interaction, and activity both in physiological and disease states. MS technologies were implemented as important tools to characterize and discover novel PTMs (Wang et al., 2019). PTMomics, which is the MS-based qualitative and quantitative analysis of PTMs in a given organism or cell, holds great potential to elucidate disease mechanisms by providing knowledge on the nature and regulation of PTMs, contributing significantly to structural and functional proteomic studies. However, the MS-based analysis of PTMs poses significant technical challenges due to the low-abundance and lability of PTM-modified peptides. Development of sensitive PTM enrichment methods could facilitate the identification and quantification of PTMs in complex samples. In the work by Ye et al., high-affinity antibody enrichment combined with high-resolution LC-MS/MS is used to systematically investigate acidic lysine acylations (malonylation, succinylation, and glutarylation) in Mycobacterium smegmatis, with protein-protein interaction networks and pathway enrichment analysis suggesting a complex mechanism through which Mycobacteria might adapt to the host cellular environment manipulating the host’s metabolic environment. Interestingly, these authors imply the potential utility of acidic acylations as biomarkers or therapeutic targets.
Understanding the complexity of proteoforms, i.e., protein variants generated by mutations, alternate splicing, mRNA processing and PTMs, is crucial for the selection of biomarkers, therapeutic targets and drug candidates. By using commercial, highly purified serum albumin as a model, Woodland et al. show how the most common current analytical MS approaches (shotgun or bottom-up proteomics and mass spectrometry-intensive top-down proteomics) both fail to fully and effectively identify proteoforms and/or provide their comprehensive analysis, proposing high-resolution, quantitative integrated/integrative top-down proteomics as a better approach while raising interesting questions in readers’ minds.
To circumvent analytical challenges, several computational approaches have been developed to study PTMs, such as phosphorylation, glycosylation, S-nitrosylation, methylation, sumoylation, palmitoylation, and N-myristoylation (Audagnotto and Dal Peraro, 2017). These in silico bioinformatics tools could predict modified sites that can be then validated with experimental approaches, expanding the scope of PTM studies. In this research topic, Zhang et al. applied deep learning combined with attention mechanism to develop a tool called DeepO-GlcNAc for prediction of protein O-GlcNAcylation. It showed that DeepO-GlcNAc predictor achieved remarkable performance in prediction of O-GlcNAc sites with an accuracy of 92% and an average precision of 72%. This DeepO-GlcNAc predictor is a valuable tool for future research in protein O-GlcNAcylation.
Gastrointestinal dysfunctions are often associated with type 2 diabetes mellitus (T2DM), a complicated metabolic illness. Since pathophysiology remains unknown, it is critically important to investigate risk factors and preventative strategies for gastrointestinal disorders linked to T2DM. Zhang et al. performed a comprehensive analysis of the gastric sinus metabolome, transcriptome, and proteome in db/db mice to explore the possible causes behind gastrointestinal dysfunctions caused by T2DM. The authors used multi-omics research to reveal and prove that genes, proteins, and metabolites in the T2DM-induced gastroenteropathy mice group were involved in arachidonic acid metabolism, glycerophospholipid metabolism and vitamin digestion and absorption, which would provide vital understandings of the pathophysiology.
Given the complexity of biological systems, single omics analyses cannot provide a comprehensive understanding of molecular changes of complex diseases. Multi-omics, which combines two or more omics, such as genomics, transcriptomics, proteomics, metabolomics, could provide an integrated approach for deeper insights and discoveries and promote the understanding of human diseases (Chen et al., 2020).
XC: Writing–original draft, Writing–review and editing. YL: Writing–review and editing. DB: Writing–review and editing.
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declare that no Generative AI was used in the creation of this manuscript.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Audagnotto, M., and Dal Peraro, M. (2017). Protein post-translational modifications: in silico prediction tools and molecular modeling. Comput. Struct. Biotechnol. J. 15, 307–319. doi:10.1016/j.csbj.2017.03.004
Chen, C., Wang, J., Pan, D., Wang, X., Xu, Y., Yan, J., et al. (2020). Applications of multi-omics analysis in human diseases. MedComm 4 (4): e315, doi:10.1002/mco2.315
Chen, X., Sun, Y., Zhang, T., Shu, L., Roepstorff, P., and Yang, F. (2021). Quantitative proteomics using isobaric labeling: a practical guide. Genomics Proteomics Bioinforma. 19 (5), 689–706. doi:10.1016/j.gpb.2021.08.012
Chew, N. W. S., Ng, C. H., Tan, D. J. H., Kong, G., Lin, C., Chin, Y. H., et al. (2023). The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 35 (3), 414–428.e3. doi:10.1016/j.cmet.2023.02.003
Martinez-Val, A., Guzmán, U. H., and Olsen, J. V. (2022). Obtaining complete human proteomes. Annu. Rev. Genomics Hum. Genet. 23, 99–121. doi:10.1146/annurev-genom-112921-024948
Keywords: proteomics, PTMomics, metabolic diseases, proteoform, cellular pathology
Citation: Chen X, Li Y and Braconi D (2025) Editorial: Advancements in proteomics and PTMomics: unveiling mechanistic insights and targeted therapies for metabolic diseases. Front. Cell Dev. Biol. 13:1556129. doi: 10.3389/fcell.2025.1556129
Received: 06 January 2025; Accepted: 10 January 2025;
Published: 24 January 2025.
Edited and reviewed by:
Kunihiro Tsuchida, Fujita Health University, JapanCopyright © 2025 Chen, Li and Braconi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiulan Chen, Y2hlbnhpdWxhbkBtb29uLmlicC5hYy5jbg==; Yanchang Li, bGl5YW5jaGFuZzEwMTdAMTYzLmNvbQ==; Daniela Braconi, ZGFuaWVsYS5icmFjb25pQHVuaXNpLml0
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.